Skip to content

Study · Non-randomized trial · n = 16 · 2009

19 results

Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.

Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J

Bone17 Oct 2008Cited by 61 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. 19 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, cancellous bone volume was 45-48% higher after PTH(1-84) than placebo at 18 months.

    In plain wordsIn women with osteoporosis, cancellous bone volume was 45-48% higher with PTH than placebo at 18 months.

    Outcome
    IncreaseCancellous bone volume
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Measurements

    Cancellous bone volume (BV/TV) higher with PTH(1-84) versus placebo
    45 to 48%
    18 months, microCT and histomorphometry

    Source sentences

    Summary
    At 18 months, cancellous bone volume (BV/TV) measured by microcomputed tomography and histomorphometry was 45-48% higher in subjects treated with PTH(1-84) versus placebo, a result of higher trabecular number (Tb.N) and thickness.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  2. 02HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, PTH(1-84) increased trabecular number versus placebo at 18 months.

    In plain wordsIn women with osteoporosis, trabecular number was higher with PTH than placebo.

    Outcome
    IncreaseTrabecular number
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    At 18 months, cancellous bone volume (BV/TV) measured by microcomputed tomography and histomorphometry was 45-48% higher in subjects treated with PTH(1-84) versus placebo, a result of higher trabecular number (Tb.N) and thickness.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  3. 03HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, PTH(1-84) increased trabecular thickness versus placebo at 18 months.

    In plain wordsIn women with osteoporosis, trabecular thickness was higher with PTH than placebo.

    Outcome
    IncreaseTrabecular thickness
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    At 18 months, cancellous bone volume (BV/TV) measured by microcomputed tomography and histomorphometry was 45-48% higher in subjects treated with PTH(1-84) versus placebo, a result of higher trabecular number (Tb.N) and thickness.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  4. 04HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, connectivity density was higher with PTH(1-84) than placebo.

    In plain wordsIn women with osteoporosis, bone connectivity density was higher with PTH than placebo.

    Outcome
    IncreaseConnectivity density
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Connectivity density was higher and structure model index was lower, indicating a better connected and more plate-like trabecular architecture.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  5. 05HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, structure model index was lower with PTH(1-84) than placebo.

    In plain wordsIn women with osteoporosis, bone structure model index was lower with PTH than placebo.

    Outcome
    DecreaseStructure model index
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Connectivity density was higher and structure model index was lower, indicating a better connected and more plate-like trabecular architecture.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  6. 06HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, cancellous bone formation rate was 2-fold higher with PTH(1-84) than placebo.

    In plain wordsIn women with osteoporosis, cancellous bone formation was 2-fold higher with PTH than placebo.

    Outcome
    IncreaseCancellous bone formation rate
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Measurements

    Cancellous bone formation rate with PTH(1-84) versus placebo
    2 fold
    PTH(1-84)-treated subjects

    Source sentences

    Summary
    Cancellous bone formation rate (BFR) was 2-fold higher in PTH(1-84)-treated subjects, primarily because of greater mineralizing surface.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  7. 07HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, mineralizing surface was greater with PTH(1-84) than placebo.

    In plain wordsIn women with osteoporosis, mineralizing bone surface was greater with PTH than placebo.

    Outcome
    IncreaseMineralizing surface
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Cancellous bone formation rate (BFR) was 2-fold higher in PTH(1-84)-treated subjects, primarily because of greater mineralizing surface.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  8. 08HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, osteoblast surface was nonsignificantly 58% higher with PTH(1-84) than placebo.

    In plain wordsIn women with osteoporosis, osteoblast surface was 58% higher with PTH than placebo, without statistical significance.

    Outcome
    IncreaseOsteoblast surface
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Measurements

    Osteoblast surface higher with PTH(1-84)
    58%
    reported as nonsignificant

    Source sentences

    Summary
    Osteoblast and osteoid surfaces were a nonsignificant 58% and 35%, respectively, higher with PTH(1-84) treatment.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  9. 09HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, osteoid surface was nonsignificantly 35% higher with PTH(1-84) than placebo.

    In plain wordsIn women with osteoporosis, osteoid surface was 35% higher with PTH than placebo, without statistical significance.

    Outcome
    IncreaseOsteoid surface
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Measurements

    Osteoid surface higher with PTH(1-84)
    35%
    reported as nonsignificant

    Source sentences

    Summary
    Osteoblast and osteoid surfaces were a nonsignificant 58% and 35%, respectively, higher with PTH(1-84) treatment.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  10. 10HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, PTH(1-84) did not affect osteoclast surface versus placebo.

    In plain wordsIn women with osteoporosis, PTH did not affect osteoclast surface versus placebo.

    Outcome
    No significant changeOsteoclast surface
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Osteoclast and eroded surface were unaffected by PTH(1-84).
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  11. 11HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, PTH(1-84) did not affect eroded surface versus placebo.

    In plain wordsIn women with osteoporosis, PTH did not affect eroded bone surface versus placebo.

    Outcome
    No significant changeEroded surface
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Osteoclast and eroded surface were unaffected by PTH(1-84).
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  12. 12HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, PTH(1-84) did not affect cortical thickness versus placebo.

    In plain wordsIn women with osteoporosis, PTH did not affect cortical thickness versus placebo.

    Outcome
    No significant changeCortical thickness
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no effects of PTH(1-84) treatment on cortical thickness, or endocortical or periosteal BFR, but cortical porosity tended to be higher.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  13. 13HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, PTH(1-84) did not affect endocortical bone formation rate versus placebo.

    In plain wordsIn women with osteoporosis, PTH did not affect endocortical bone formation versus placebo.

    Outcome
    No significant changeEndocortical bone formation rate
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no effects of PTH(1-84) treatment on cortical thickness, or endocortical or periosteal BFR, but cortical porosity tended to be higher.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  14. 14HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, PTH(1-84) did not affect periosteal bone formation rate versus placebo.

    In plain wordsIn women with osteoporosis, PTH did not affect periosteal bone formation versus placebo.

    Outcome
    No significant changePeriosteal bone formation rate
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no effects of PTH(1-84) treatment on cortical thickness, or endocortical or periosteal BFR, but cortical porosity tended to be higher.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  15. 15HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, cortical porosity tended to be higher with PTH(1-84) than placebo.

    In plain wordsIn women with osteoporosis, cortical porosity tended to be higher with PTH than placebo.

    Outcome
    IncreaseCortical porosity
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no effects of PTH(1-84) treatment on cortical thickness, or endocortical or periosteal BFR, but cortical porosity tended to be higher.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  16. 16HumanNon-randomized trialEfficacy outcome

    In osteoporotic women receiving PTH(1-84), cancellous bone formation rate was lower at 24 than at 18 months.

    In plain wordsIn women receiving PTH, cancellous bone formation was lower at 24 than at 18 months.

    Outcome
    DecreaseCancellous bone formation at 24 versus 18 months
    Study

    n = 15

    Comparator
    18 months
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Although cancellous BFR was lower at 24 than at 18 months, measures of cancellous and cortical bone structure were similar at both timepoints.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  17. 17HumanNon-randomized trialEfficacy outcome

    In osteoporotic women receiving PTH(1-84), cancellous and cortical structure measures were similar at 24 and 18 months.

    In plain wordsIn women receiving PTH, cancellous and cortical bone structure was similar at 24 and 18 months.

    Outcome
    Direction not reportedCancellous and cortical structure over time
    Study

    n = 15

    Comparator
    18 months
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Although cancellous BFR was lower at 24 than at 18 months, measures of cancellous and cortical bone structure were similar at both timepoints.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  18. 18HumanNon-randomized trialSafety outcome

    In osteoporotic women, bone produced during PTH(1-84) treatment had normal lamellar structure and mineralization without abnormal histology.

    In plain wordsIn women with osteoporosis, bone produced during PTH treatment had normal structure and mineralization without abnormal histology.

    Outcome
    Not applicableBone histology
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microgAs given in this study (human).

    Source sentences

    Summary
    The bone produced by PTH(1-84) had normal lamellar structure and mineralization with no abnormal histology.
    1 context sentence
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
  19. 19HumanNon-randomized trialMechanism

    In osteoporotic women given PTH(1-84), higher trabecular number appeared to result from intratrabecular tunneling.

    In plain wordsIn women given PTH, higher trabecular number appeared to result from tunneling within bone struts.

    Outcome
    Direction not reportedIntratrabecular tunneling and trabecular number
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The higher Tb.N appeared to result from intratrabecular tunneling.
    2 context sentences
    Summary · context
    We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure.
    Summary · context
    At 18 months, cancellous bone volume (BV/TV) measured by microcomputed tomography and histomorphometry was 45-48% higher in subjects treated with PTH(1-84) versus placebo, a result of higher trabecular number (Tb.N) and thickness.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.